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In the UK, heart and circulatory diseases account for 29% of all deaths (14% through
coronary heart disease and 8% through stroke). In 2015, the prevalence of hyperten-
sion was 20% in the UK and 23% in the Republic of Ireland. In 2019, 14% of people
registered with a UK general practice had hypertension and yet it was the attribut-
able risk factor for around half of all deaths from coronary heart disease or stroke.
We participated in May Measurement Month 2019 to increase awareness of blood
pressure (BP) measurement, and to identify the proportion of undiagnosed hyperten-
sion and degree of uncontrolled hypertension in the community. The 2019 campaign
set up screening sites within the community at places of worship, supermarkets, GP
surgeries, workplaces, charity events, community pharmacies, gyms, and various
other public places. We screened 10194 participants (mean age 516 18 years, 60%
women) and found that 1013 (9.9%) were on antihypertensive treatment, while 3408
(33.4%) had hypertension. Of the 3408 participants with hypertension, only 33.5%
were aware of their condition despite 98.8% having previous BP measurements. In
those on antihypertensive medication, only 38.2% had controlled BP (<140 and <90
mmHg). Our UK and Republic of Ireland data demonstrate concerning levels of
undiagnosed hypertension and sub-optimal BP control in many individuals with a
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diagnosis. This evidence supports a critical need for better systematic community
and primary care screening initiatives.
Introduction
Raised blood pressure (BP) is the biggest single risk factor
contributing to the global burden of disease.1 In the UK,
heart and circulatory diseases account for 29% of all deaths
(14% through coronary heart disease and 8% through
stroke). These figures have not improved significantly since
2011 despite national strategies targeted at improved diag-
nosis and treatment. Furthermore, data from 2015
highlighted that prevalence of raised BP (140 and/or
90mmHg) was 20% in the UK and 23% in the Republic of
Ireland.2 In 2019, 14% of people registered with a UK gen-
eral practice had hypertension and yet it was the attribut-
able risk factor for around half of all deaths from coronary
heart disease or stroke.3 These data suggest that the true
prevalence of hypertension is higher than is suggested by
primary care registries and that sub-optimal management
of this risk factor is limiting our ability to positively improve
outcomes.
Our goal in participating in the May Measurement Month
(MMM) campaign was to assess the extent of undiagnosed
high BP in community settings and to raise public aware-
ness of the importance of BP screening. The 2017 UK and
Republic of Ireland campaign screened 7695 participants.
Of these, 40.3% had hypertension and 21.9% reported tak-
ing antihypertensive medications. Of those with known hy-
pertension, only 59.5% had BP within treatment targets
(<140/<90mmHg).4 The 2018 campaign screened 5000
participants and found 34.3% to have high BP, of whom
42.8% reported taking antihypertensive treatment and only
51.5% of those on medication had BP within treatment
targets.5
Our aim for the 2019 campaign was to ascertain whether
these annual figures were stable estimates of undiagnosed
hypertension in the community and indicators of sub-
optimal BP control in those with hypertension.
Methods
In May 2019, community-based opportunistic screening
sites were set-up and directed by MMM country leads in
England, Scotland, Wales, and the Republic of Ireland.
Ethical approval was granted and covered all UK based BP
screening events. Over 200 sites were set up and per-
formed BP screening on individuals aged 18 years and older,
as part of the campaign. Community screening sites in-
cluded places of worship, supermarkets, GP surgeries,
charity events, workplaces, community pharmacies, gyms,
and various other public places. Investigator-lead training
days for partners and those taking part in BP screening
were conducted prior to screening events. Similar to previ-
ous years, Omron provided BP devices to national partners
that did not have access to validated systems. In Wales,
Cardiff Metropolitan University provided funding for mar-
ketingmaterial and promotional purposes. Similar to previ-
ous years, the Academy of Medical sciences INSPIRE
provided funding for similar promotional and marketing
purposes in England. Governmental, celebrity, public
health, and British Heart Foundation endorsements via so-
cial media, national webpages, and newspaper articles
were used to promote the campaign locally and nationally.
Screenings events were undertaken each day of May across
the UK and Republic of Ireland. Only validated BP monitors
agreed by International Society of Hypertension were used
and three measurements conducted after 5 min of rest in
the seated position, with the average of the second and
third measurements used for analysis. For the purposes of
this paper, the term ‘hypertension’ was used when meas-
urements at the event included a systolic BP 140mmHg
and or diastolic BP90mmHg or on antihypertensivemedi-
cation(s). In addition to data collected during the 2017 and
2018 campaign, new variables detailing the type of screen-
ing event and whether the participant was aware if they
had high BP, were recorded. Similar to previous years, data
were collected using the MMM App/excel file or hard copy.
All data were processed locally by the British and Irish
Hypertension Society or MMM lead in Wales. Data were ana-
lysed centrally by the MMM project team and multiple im-
putation performed to impute the mean of readings 2 and
3, where this was missing.6 The data underlying this article
will be shared on reasonable request to the corresponding
author.
Results
Data on 10 194 participants were submitted as part of MMM
2019 for the UK and Republic of Ireland. The mean age of
participants was 516 18 years, with a gender ratio of ap-
proximately 60% female and 40% male. Of the 10 194 par-
ticipants screened, 1013 (9.9%) were on antihypertensive
treatment. Data were collected across a range of ethnic
groups [South Asian: 206 (2%), East Asian: 46 (0.5%), Black:
154 (1.5%), South East Asian: 58 (0.6%), White: 3132
(30.7%), Arabic: 55 (0.5%), Mixed: 67 (0.7%), Other: 89
(0.9%) and uncategorized or Unknown: 6387 (62.7%)]. Only
127 (1.2%) of participants had never had BP measured be-
fore the screening event. Of those screened, 237 (2.3%)
were currently taking statins, 75 (0.7%) were taking
Aspirin, 2.9% reported as having diabetes, 0.6% as having a
previous myocardial infarction, and 0.7% a previous stroke.
Of the 10 194 participants measured, 3408 (33.4%) were
identified as having hypertension. Of all 3408 participants
with hypertension, 33.5% were aware of their condition
and 29.7% were on antihypertensive medication. Of the
1013 participants on antihypertensive medication, 38.2%
had controlled BP (<140 and <90 mmHg). See Table 1 for
more details.
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Importantly, of the 9181 participants not on antihyper-
tension medication, 2395 (26.1%) were defined as
hypertensive.
Discussion
Our 2019 MMM data show a lower proportion of hyperten-
sives in the UK and Republic of Ireland compared with
Europe (33.4% vs. 43.6%).6 However, those who were iden-
tified as hypertensive in the UK and Republic of Ireland had
significantly lower levels of awareness (33.5% vs. 71.5%)
and lower levels of BP control (to <140/<90 mmHg) when
taking antihypertensive medication(s) (38.2% vs. 47.9%).6
These important findings further emphasize the need for a
more focused primary care and community-based BP
awareness campaigns to address these significant inequal-
ities of risk.
The proportion of people identified as hypertensive
(33.4%) in this current 2019 dataset was similar to data
from 2018 but not 2017, which reported levels as high as
40%. Importantly, these current data identify 33.4% of
those screened as having hypertension (140/90 mmHg
or being on antihypertensive medication), which is higher
than the reported prevalence from GP registries and the
Public Health England (PHE) estimates of 26.2% published
in 2016.7 The differences observed may reflect the PHE
data as ‘estimates’, which have been based upon data
gathered from GP practices and public health data in
England only. These differences may in part reflect that
the MMM data are based on opportunistic convenience sam-
pling and may not be nationally representative.
Furthermore, being based on only one set of readings they
may be spuriously high. However, these differences might
also highlight the potential for ‘estimates’ to underrepre-
sent the prevalence of hypertension and extent of the
problem in the wider community.
The NHS England Long Term Plan identifies cardiovascu-
lar disease as a clinical priority and sets a target of prevent-
ing 150 000 heart attacks, strokes, and dementia cases
over a 10-year period though national prevention pro-
grammes such as ‘know your ABCs’ (which includes BP) and
NHS health checks for those aged 40–75 years.8 In fact, the
British Heart Foundation Cymru launched their political
manifesto to Wales Government in November 2020. This
manifesto paper described the critical need for early de-
tection of raised BP and appropriate BP control as one of
three key cardiovascular health measures to address for
Wales Government. Our data highlight that only 1.2% of
people screened had never had their BP measured before
the event, which suggests that accessibility to measuring
BP is not a public health issue in the UK and Republic of
Ireland. However, what is of major concern is the popula-
tion’s lack of awareness of their raised BP and the lack of
adequate BP control in those with diagnosed hypertension.
This evidence supports a critical need for better commu-
nity and primary care initiatives which highlight the need
to identify and act on raised BP, implementing more effec-
tive strategies to improve BP control. Only then will we
minimize population cardiovascular risk and national eco-
nomic burden of disease associatedwith hypertension.
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